{
    "project_id": "171229",
    "broad_study_type": "trial",
    "narrow_study_type": "randomized_controlled_trial",
    "trial_phase": "4",
    "observational_timeframe": "N/A",
    "justification": "Our primary objective is to conduct a randomized controlled trial (RCT) that will compare the clinical effectiveness and cost-effectiveness of two treatment strategies for patients with persistent depression: 1) Algorithm-based Pharmacotherapy plus manual-based cognitive-behavioural therapy (CBT), and 2) Algorithm-based Pharmacotherapy plus treatment as usual (TAU) by the family physician (FP).",
    "data_type": "canadian",
    "ipd_used": "individual",
    "novelty_statement": "This study will determine whether this combined treatment model will offer any advantages over usual specialty mental health services, and if so, at what cost.",
    "replication_study": "no",
    "target_population_size": "260",
    "age_range": "adults",
    "gender_focus": "mixed",
    "vulnerable_populations": "yes",
    "rare_disease": "no",
    "population_description": "primary care patients with persistent depression",
    "intervention_category": "psychosocial_behavioral",
    "intervention_name": "cognitive-behavioural therapy",
    "control_type": "active_control",
    "dose_response": "no",
    "combination_therapy": "yes",
    "personalized_medicine": "no",
    "primary_outcome": "depressive symptoms",
    "primary_outcome_type": "symptom_score",
    "safety_focus": "no",
    "quality_of_life": "yes",
    "biomarker_endpoints": "no",
    "time_to_event": "no",
    "composite_endpoint": "no",
    "ai_machine_learning": "no",
    "digital_health": "no",
    "telemedicine": "no",
    "wearable_technology": "no",
    "big_data_analytics": "no",
    "blockchain": "no",
    "cost_effectiveness": "yes",
    "budget_impact": "yes",
    "health_technology_assessment": "yes",
    "resource_utilization": "yes",
    "productivity_outcomes": "no",
    "implementation_science": "yes",
    "policy_evaluation": "yes",
    "health_system_integration": "yes",
    "scalability_assessment": "yes",
    "barrier_identification": "no",
    "adaptive_design": "no",
    "bayesian_methods": "no",
    "machine_learning_analysis": "no",
    "novel_biostatistics": "no",
    "patient_reported_outcomes": "yes",
    "real_world_evidence": "yes",
    "industry_partnership": "no",
    "patient_engagement": "yes",
    "community_based": "yes",
    "indigenous_collaboration": "no",
    "international_collaboration": "no",
    "international_network": "no",
    "regulatory_pathway": "no",
    "ethics_focus": "yes",
    "consent_innovation": "no",
    "data_sharing": "no",
    "therapeutic_area": "mental_health",
    "disease_stage": "chronic",
    "comorbidity_focus": "no",
    "pandemic_related": "no",
    "environmental_health": "no",
    "social_determinants": "no",
    "health_equity": "no",
    "climate_health": "no",
    "urban_rural": "unclear",
    "biobank_use": "no",
    "registry_linkage": "no",
    "cohort_establishment": "no",
    "platform_trial": "no",
    "study_duration": "long_term",
    "multicenter": "no",
    "healthcare_setting": "primary_care",
    "disease_area": "depression",
    "methodology_innovation": "randomized controlled trial comparing combined pharmacotherapy and CBT to pharmacotherapy plus usual care for persistent depression in a primary care setting, including a cost-effectiveness analysis",
    "knowledge_translation_focus": "yes",
    "equity_considerations": "no"
} 